EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lattice Biologics's enterprise value is $0.00 Mil.
Lattice Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00 Mil. Therefore, Lattice Biologics's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Lattice Biologics's EV-to-EBITDA or its related term are showing as below:
LBLTF's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.405 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Lattice Biologics EV-to-EBITDA Historical Data
The historical data trend for Lattice Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lattice Biologics's EV-to-EBITDA
For the Medical Devices subindustry, Lattice Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lattice Biologics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lattice Biologics's EV-to-EBITDA falls into.
Lattice Biologics's current Enterprise Value is $0.00 Mil.
Lattice Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Lattice Biologics's PE Ratio for today is calculated as:
Lattice Biologics's share price for today is $0.0001.
Lattice Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Lattice Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Lattice Biologics (Lattice Biologics) Business Description
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LBLTF has been successfully added to your 